Bennett Berson helped global clients with their most complex, cutting-edge intellectual property needs, provided experienced counsel and thought leadership in the biotechnology space. Bennett worked closely with a wide range of businesses and research institutions to evaluate critical intellectual property opportunities for today's breakthroughs with an eye on how those innovations will evolve tomorrow.

Bennett devoted much of his practice to protecting intellectual property around creating and using human pluripotent stem cells, one of the most important and game-changing scientific breakthroughs of our time. He not only counseled on the current stem cell intellectual property landscape, but looked ahead to new developments on the horizon. Bennett also had significant IP experience pertaining to next-generation sequencing and regularly helped clients identify patent-eligible inventions arising out of clinically-relevant genomic, proteomic, metabolomic, and pharmaceutical investigations. He spoke regularly on a range of intellectual property matters, including strategies and insight pertaining to new U.S. Patent Office practices implemented following the U.S. Supreme Court's recent Prometheus, Myriad, and Alice decisions.

Bennett devised and implemented strategies for creating, maintaining, and enforcing trademark and patent properties for large and small clients in the United States and around the globe, advised on pre- and post-acquisition strategies including patent litigation, patent oppositions, trademark opposition, and cancellation proceedings.

Bennett was active in the International Trademark Association and the Association of University Technology Managers. He represented the intellectual property needs of a broad range of clients, from the most sophisticated industry leaders to small and mid-level local companies and organizations.